CN115397462A - 个体化治疗性抗癌疫苗 - Google Patents

个体化治疗性抗癌疫苗 Download PDF

Info

Publication number
CN115397462A
CN115397462A CN202180027619.XA CN202180027619A CN115397462A CN 115397462 A CN115397462 A CN 115397462A CN 202180027619 A CN202180027619 A CN 202180027619A CN 115397462 A CN115397462 A CN 115397462A
Authority
CN
China
Prior art keywords
patient
antigenic
sequence
unit
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027619.XA
Other languages
English (en)
Chinese (zh)
Inventor
阿涅特·布伦斯维克·弗雷德里克森
莫妮卡·塞克利亚
卡罗琳·施杰田纳
斯蒂因·格拉纳姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Necord Therapeutics Ltd
Original Assignee
Necord Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Necord Therapeutics Ltd filed Critical Necord Therapeutics Ltd
Publication of CN115397462A publication Critical patent/CN115397462A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180027619.XA 2020-04-09 2021-04-09 个体化治疗性抗癌疫苗 Pending CN115397462A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA202070221 2020-04-09
DKPA202070221 2020-04-09
DKPA202070338 2020-05-26
DKPA202070338 2020-05-26
PCT/EP2021/059353 WO2021205027A1 (en) 2020-04-09 2021-04-09 Individualized therapeutic anticancer vaccine

Publications (1)

Publication Number Publication Date
CN115397462A true CN115397462A (zh) 2022-11-25

Family

ID=75539309

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027619.XA Pending CN115397462A (zh) 2020-04-09 2021-04-09 个体化治疗性抗癌疫苗

Country Status (11)

Country Link
US (1) US20230293650A1 (https=)
EP (1) EP4132565A1 (https=)
JP (1) JP2023522588A (https=)
KR (1) KR20230004585A (https=)
CN (1) CN115397462A (https=)
AU (1) AU2021252155A1 (https=)
BR (1) BR112022020277A2 (https=)
CA (1) CA3172191A1 (https=)
IL (1) IL297049A (https=)
MX (1) MX2022012671A (https=)
WO (1) WO2021205027A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230164118A (ko) 2021-03-26 2023-12-01 니코데 테라퓨틱스 에이에스에이 암 치료를 위한 치료 조합
WO2022233851A1 (en) 2021-05-03 2022-11-10 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
BR112023023260A2 (pt) 2021-05-10 2024-01-30 Nykode Therapeutics ASA Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014015016B1 (pt) 2011-12-21 2023-10-03 Nykode Therapeutics ASA Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina
EP3417874B1 (en) * 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
IL260030B2 (en) * 2016-01-08 2025-12-01 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine

Also Published As

Publication number Publication date
JP2023522588A (ja) 2023-05-31
AU2021252155A1 (en) 2022-12-08
BR112022020277A2 (pt) 2023-02-14
WO2021205027A1 (en) 2021-10-14
EP4132565A1 (en) 2023-02-15
IL297049A (en) 2022-12-01
US20230293650A1 (en) 2023-09-21
CA3172191A1 (en) 2021-10-14
MX2022012671A (es) 2023-01-05
KR20230004585A (ko) 2023-01-06

Similar Documents

Publication Publication Date Title
JP7535489B2 (ja) 治療用抗癌ネオエピトープワクチン
CN115397462A (zh) 个体化治疗性抗癌疫苗
CN109575142B (zh) 一种cd4辅助性t细胞表位融合肽及其疫苗
JP6406647B2 (ja) 細胞性免疫誘導ワクチン
WO2017118702A1 (en) Neoepitope rna cancer vaccine
WO2013006050A1 (en) Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA)
RU2850342C1 (ru) Индивидуализированная терапевтическая противораковая вакцина
Wang et al. Designing multifunctional recombinant vaccines: an engineering strategy based on innovative epitope prediction-guided splicing
EP4337248A2 (en) Co-expression of constructs and immunostimulatory compounds
RU2782422C2 (ru) Терапевтическая противораковая неоэпитопная вакцина
WO2024092025A1 (en) Constructs and their use
WO2022238381A2 (en) Immunotherapy constructs for treatment of disease
WO2022200590A1 (en) Therapeutic combination for treating cancer
CN118043066A (zh) 构建体和免疫刺激性化合物的共表达
BR112018013881B1 (pt) Vacina de neoepítopo anticâncer terapêutica e uso de uma vacina para tratamento de câncer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination